Yukiko Inada

Takamatsu, 8800003, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Cause-specific mortality following sustained virologic response in hepatitis C patients treated with direct-acting antivirals: a standardized mortality ratio analysis.

Cause-specific mortality following sustained virologic response in hepatitis C patients treated with direct-acting antivirals: a standardized mortality ratio analysis.

Journal: Scientific reports

Published: September 26, 2025

Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus.

Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus.

Journal: PloS one

Published: September 05, 2021

Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.

Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.

Journal: PloS one

Published: May 29, 2020

Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy.

Viral and host factors are associated with retreatment failure in hepatitis C patients receiving all-oral direct antiviral therapy.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: August 13, 2019

Effect of tolvaptan on the prognosis of patients with hepatic ascites.

Effect of tolvaptan on the prognosis of patients with hepatic ascites.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: October 17, 2018

The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.

The co-existence of NS5A and NS5B resistance-associated substitutions is associated with virologic failure in Hepatitis C Virus genotype 1 patients treated with sofosbuvir and ledipasvir.

Journal: PloS one

Published: March 28, 2018

Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.

Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.

Journal: Journal of gastroenterology

Published: September 25, 2017

New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.

New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.

Journal: Journal of gastroenterology

Published: September 05, 2016

Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.

Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.

Journal: Journal of gastroenterology

Published: April 13, 2016

A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.

A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3.

Journal: SpringerPlus

Published: December 21, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026